Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirozadil
- Development stage
- Unknown
- Lead developer
- Currax Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pirozadil is a small molecule antilipidemic agent classified as a nicotinic acid derivative and a trihydroxybenzoic acid. It is used for the treatment of type IIa hyperlipidemia and has been shown to reduce triglycerides, total cholesterol, and LDL-cholesterol in patients with hypercholesterolemia. Its primary mechanism is lipid-lowering, and it is considered potentially useful in preventing atherosclerotic disease[1][3][4][6][7][8][10].
- Brand names
- Calpatil
- Other names
- PemixPirozadilum
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on pirozadil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirozadil.